Bukwang Pharmaceutical Completes Phase 1 Clinical Trial of Prostate Cancer Treatment 'SOL-804'

[Asia Economy Reporter Chunhee Lee] Bukwang Pharmaceutical announced on the 30th that it has completed the Phase 1 clinical trial of the anticancer drug 'SOL-804,' which is being developed through its subsidiary Dynacera Therapeutics.

Bukwang Pharmaceutical stated, "Compared to the existing drug Xtiga, significant pharmacokinetic characteristics were confirmed in the results using a low dose," adding, "Meaningful results were obtained."

This clinical trial was conducted at Seoul National University Hospital with 40 participants, using a randomized, crossover, single-dose administration method. It was carried out to compare the safety, tolerability, and pharmacokinetic characteristics of SOL-804, which improves the absorption rate of the existing drug, with Xtiga tablets.

SOL-804 is a modified new drug aimed at improving the absorption rate and food effects, which are weaknesses of existing treatments for metastatic castration-resistant prostate cancer. The company explained, "It is expected to increase patient convenience and medication adherence."

Based on the results of this clinical trial, Bukwang Pharmaceutical plans to establish a strategy for future approval and conduct additional clinical trials, including studies to improve the effects of food. Dynacera Therapeutics acquired the global development and marketing rights for SOL-804 exclusively from Denmark's Solural Pharma in 2016 and is developing it independently.

This content was produced with the assistance of AI translation services.